KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Gross Margin (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 15 years of Gross Margin data on record, last reported at 86.25% in Q2 2025.

  • For Q2 2025, Gross Margin rose 31.0% year-over-year to 86.25%; the TTM value through Jun 2025 reached 84.94%, down 151.0%, while the annual FY2025 figure was 86.24%, 13.0% up from the prior year.
  • Gross Margin reached 86.25% in Q2 2025 per VRTX's latest filing, up from 85.46% in the prior quarter.
  • Across five years, Gross Margin topped out at 88.85% in Q1 2021 and bottomed at 85.38% in Q4 2023.
  • Average Gross Margin over 5 years is 87.27%, with a median of 87.6% recorded in 2022.
  • Peak YoY movement for Gross Margin: skyrocketed 79bps in 2022, then crashed -231bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 88.06% in 2021, then decreased by 0bps to 87.7% in 2022, then dropped by -3bps to 85.38% in 2023, then increased by 0bps to 85.46% in 2024, then increased by 1bps to 86.25% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 86.25% in Q2 2025, 85.46% in Q4 2024, and 85.84% in Q3 2024.